NCT07294508 2025-12-29
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
Clinical Trials
3 trialsNCT07294534 2025-12-19
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT06891833 2025-10-02
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Recruiting